TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions.

Abstract

Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.

• Authors: Giandomenico Roviello, Alberto D'Angelo, Marianna Sciortino, Enrico Mini, Stefania Nobili, Francesco De Logu, Daniela Massi
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 152 Pg. 103011 (Aug 2020) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 32521311 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Elsevier B.V. All rights reserved.

Chemical References

• Oncogene Proteins, Fusion
• Protein Kinase Inhibitors

Topics

• Humans
• Neoplasms (drug therapy)
• Oncogene Proteins, Fusion
• Protein Kinase Inhibitors (therapeutic use)